Second-line cabozantinib versus nivolumab in advanced renal cell carcinoma: Systematic review and indirect treatment comparison
| Autor: | Camillo Porta, Cezary Szczylik, H Karcher, Shuai Fu, Jerome Dinet, Johanna Lister, Roman Casciano, Jie Meng, Monika Neumann, Billy Amzal |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Oncology medicine.medical_specialty Cabozantinib Pyridines 03 medical and health sciences chemistry.chemical_compound Antineoplastic Agents Immunological 0302 clinical medicine Second line Renal cell carcinoma Indirect Treatment Internal medicine medicine Humans Anilides Carcinoma Renal Cell business.industry Significant difference Treatment options Hematology medicine.disease Kidney Neoplasms Nivolumab Treatment Outcome 030104 developmental biology Data extraction chemistry 030220 oncology & carcinogenesis business |
| Zdroj: | Critical Reviews in Oncology/Hematology. 139:143-148 |
| ISSN: | 1040-8428 |
| DOI: | 10.1016/j.critrevonc.2018.10.004 |
| Popis: | Background Nivolumab and cabozantinib, two new treatment options for previously-treated advanced/metastatic renal cell carcinoma (aRCC), have recently been approved. Methods Two independent reviewers performed study selection, data extraction, and risk of bias assessment. Indirect treatment comparisons were carried out by directly assessing HR differences and statistical modeling of Kaplan-Meier curves from these two trials. Results Publications identified showed that no head-to-head comparisons had been carried out. Two indirect treatment comparisons used agreed that there was no significant difference in OS between cabozantinib and nivolumab and that cabozantinib significantly improved PFS compared to nivolumab. Conclusions The field of aRCC treatments is evolving rapidly, creating opportunities for individualized treatments and challenges for clinicians to keep up with the evidence. In lieu of availability of direct comparisons of all options, advanced modeling results presented herein can help to inform and improve personalized treatments. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect